MC
Therapeutic Areas
EyePoint Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| DURAVYU™ (EYP-1901) | Wet Age-Related Macular Degeneration (Wet AMD) | Phase 3 |
| EYP-2301 | Serious Retinal Diseases | Pre-clinical |
Leadership Team at EyePoint Pharmaceuticals
JS
Jay S. Duker, M.D.
President & CEO and Board Director
GO
George O. Elston
Executive Vice President, Chief Financial Officer
RR
Ramiro Ribeiro, M.D., Ph.D.
Chief Medical Officer
RH
Ron Honig, Esq.
Chief Legal Officer & Company Secretary
IL
Isabelle Lefebvre
Chief Regulatory Officer
JL
Jennifer Leonard
Chief People Officer and SVP, IT
MJ
Michael J. Maciocio
Chief Manufacturing Officer
MS
Marcia Sellos-Moura, Ph.D.
Chief Scientific Officer
GA
Göran Ando, M.D.
Non-Executive Chairman, Board of Directors
NL
Nancy Lurker
Vice-Chair, Board of Directors